PCSK9 inhibitors are particularly effective in the treatment of hypercholesterolemia, lowering blood LDL cholesterol levels by inhibiting the binding of PKSK9 to the low-density lipoprotein receptor (LDLR) and promoting the uptake of LDL cholesterol into liver cells [73]. This evidence concerns the gene VLDLR and familial hypercholesterolemia.